Navigation Links
Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock
Date:9/23/2009

PASADENA, Calif., Sept. 23 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) announced today that it is commencing an underwritten public offering of 3,000,000 shares of common stock. Barclays Capital, Credit Suisse and UBS Investment Bank are acting as joint bookrunning managers in connection with the public offering. Alexandria Real Estate Equities, Inc. expects to grant the underwriters a thirty-day option to purchase up to 450,000 additional shares to cover over-allotments, if any.

The Company intends to initially use the net proceeds from this offering to reduce the outstanding balance on its unsecured line of credit. The Company may then borrow from time to time under its unsecured line of credit to provide funds for general working capital and other corporate purposes, including the repayment of debt and selective redevelopment and development of existing or new life science properties including build-to-suit projects for what the Company believes are tenants with high credit ratings on land the Company owns or on land owned by major not-for-profit institutions or universities.

Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry(R), is the largest owner and pre-eminent first-in-class REIT focused principally on science-driven cluster formation. Alexandria is the leading provider of high-quality environmentally sustainable real estate, technical infrastructure, and services to the broad and diverse life science industry. Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biopharmaceutical, medical device, product, service and translational entities, as well as government agencies. Alexandria's operating platform is based on the principle of "clustering," wit
'/>"/>

SOURCE Alexandria Real Estate Equities, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
2. Alexandria Real Estate Equities, Inc. Announces Pricing of Public Follow-On Offering of 7,000,000 Shares of Common Stock
3. Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO
4. Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results
5. Deals keep Coming in Medical real Estate
6. Millions Flowing into Medical Real Estate
7. Life Sciences Real Estate Outperforming Other Sectors
8. Miami Beach Real Estate Attorney Opens Miami Real Estate Brokerage for International Luxury Miami Beach Condo Buyers From Distressed Sellers
9. Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes
10. GSI Group Inc. to Restate Financial Results for 2006
11. Miami Beach Real Estate Attorney Announces Services to Assist Chinese and other International Real Estate Investors Purchase Discount Florida Homes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... CORAL SPRINGS, Florida , August 26, 2015 ... one of the biggest factors fueling the optimism ... FDA approvals, M&A,s, collaborations and life sciences advancements.  ... and developments are Pressure BioSciences, Inc. (OTCQB: PBIO), ... Inc. (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. ...
(Date:8/25/2015)... ... August 25, 2015 , ... A new ... cancerous is described by University of Illinois researchers in the Journal of ... , In “ Breast cancer diagnosis using spatial light interference microscopy ,” published ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... blade-based and rackmount computing infrastructure, today announced the launch of its next ... The latest system boasts two distinct, individually sledded workstation nodes in each ...
(Date:8/25/2015)... KING OF PRUSSIA, Pa. , Aug. 25, 2015 ... first patient has been enrolled in its Phase II/III ... of the company,s recombinant fusion protein linking coagulation factor ... with congenital hemophilia A or B who have developed ... therapy. The study will enroll approximately 54 male patients, ...
Breaking Biology Technology:New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Cirrascale® Announces Next Generation High Density, Two-in-One GPU Rackmount Offering Perfect for High Performance Remote Workstations 2Cirrascale® Announces Next Generation High Density, Two-in-One GPU Rackmount Offering Perfect for High Performance Remote Workstations 3CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 3CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 4
... Iowa and the University of Missouri (MU) have developed a ... mimic the disease in human infants. The striking similarities between ... CF suggest that this new model will help improve understanding ... treatments. The study is published in the Sept. 26 issue ...
... More efficient. These are the qualities that drive science ... help to speed up computers. , Scientists at the ... contribution to this field by designing a new nanotechnology ... more efficient. The new process is described in today,s ...
... Scientific Accomplishment in Complement Inhibition and,Impact of Soliris ... Sept. 25 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ... for Best Biotechnology Product for Soliris(R) (eculizumab). The ... of Soliris, and the impact the drug is,having ...
Cached Biology Technology:Researchers develop new model for cystic fibrosis 2New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 2New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 3New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 4New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 5Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 3Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 4Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 5
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/3/2015)... Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... today announced that members of the executive management team ... Crest Global Technology Leadership Forum on Tuesday, August 11, ... be held at the Sonnenalp Resort in ... may include forward-looking information. An audio webcast of the ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... The Office of Naval Research (ONR) has awarded a ... from Boston University, the University of Washington, the University ... Chapel Hill. The grant will fund a project entitled ... Strategies), which will focus on the development of unmanned ...
... Cooperation across borders and disciplines is essential ... and substantial economic damages. In 2008 Myanmar in the Indian ... associated storm surge left a trail of destruction. More than ... Netherlands, England, and Hamburg were severely affected by storm surges. ...
... spruce and mountain pine beetles in western North America,s ... decades, according to a study conducted by USDA Forest ... the September issue of the journal BioScience , ... climate change on bark beetles. "Native bark ...
Cached Biology News:BU partners in 5-year, $7.5M grant to study animal flight 2Storm Surges Congress 2010 -- scientists from 30 countries meet in Hamburg 2Risk of beetle outbreaks rise, along with temperature, in the warming West 2
Umbilical cord blood mononuclear cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
... been developed specifically for the stabilization ... microwell plates/strips. Coating Stabilizer maintains ... antibody or protein antigen portion of ... is filtered at 0.2 microns., ,Contents: ...
Biology Products: